As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.
14 Analysts have issued a Ventyx Biosciences forecast:
14 Analysts have issued a Ventyx Biosciences forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -129 -129 |
30%
30%
|
|
| EBIT (Operating Income) EBIT | -130 -130 |
30%
30%
|
|
| Net Profit | -119 -119 |
31%
31%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Raju Mohan |
| Employees | 81 |
| Founded | 2018 |
| Website | ventyxbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


